Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Lessons learned from the CLL CLARITY study and ongoing follow-up

Talha Munir • 1 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax
CLARITY

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the lessons that we have learned from the Bloodwise Trials Acceleration Programme (TAP) CLARITY study (ISCRTN13751862), which investigated venetoclax in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Dr Munir also discusses the ongoing follow-up analysis to see how durable MRD negativity was. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Talha Munir

1:21
MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL
Talha Munir • 12 Dec 2023
1:35
55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL
Talha Munir • 12 Dec 2023
2:17
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL
Talha Munir • 11 Dec 2023
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals